Background: Novel drug discovery against non-tuberculous mycobacteria is beset with a large number of challenges including the existence of myriad innate drug resistance mechanisms as well as a lack of suitable animal models, which hinders effective translation. In order to identify molecules acting via novel mechanisms of action, we screened the Library of Pharmacologically Active Compounds against non-tuberculous mycobacteria to identify such compounds.
Introduction
Non-tuberculous mycobacteria (NTM), such as Mycobacterium fortuitum, Mycobacterium abscessus, Mycobacterium avium complex and Mycobacterium chelonae, are a diverse group of environmental pathogens capable of causing opportunistic infections in humans and animals and have become one of the major threats in terms of morbidity and mortality, especially in immunecompromised individuals. 1, 2 They share the same genera as Mycobacterium tuberculosis and Mycobacterium leprae, the causative agents of TB and leprosy, respectively, but are highly dissimilar on many levels. 3 NTM infections are being increasingly reported worldwide, with M. avium complex, Mycobacterium kansasii, M. abscessus and M. fortuitum being the most frequently clinically significant NTM isolated and M. abscessus being one of the most drug-resistant mycobacteria. 4, 5 One of the major differences concerns the existing level of drug resistance; the majority of the clinically relevant NTM strains are inherently resistant to almost all classes of clinically utilized drugs including the first-line drugs (e.g. isoniazid, rifampicin and pyrazinamide) used for treatment of TB. 6 This, in combination with a lack of suitable molecular diagnostic tools, exemplifies their status as neglected pathogens.
The usual treatment of most NTM infections is a long-term multidrug regimen consisting of a macrolide, cephalosporin and a fluoroquinolone as most of these pathogens show intrinsic V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
resistance to most of the first-line anti-TB drugs. 7 Another important aspect of drug discovery against NTM is that there is often a lack of correlation between in vitro potency and clinical efficacy of compounds to completely eradicate infection, thus prolonging the drug regimen, which is associated with poor patient compliance. [8] [9] [10] [11] [12] Thus, the need of the hour is to identify novel molecules that are potently active against NTM, and do not crossreact with existing drug-resistance mechanisms.
In this context, we initiated a drug discovery programme by screening LOPAC V R (Sigma-Aldrich, St Louis, MO, USA), consisting of 1280 structurally different small molecules, and have identified diphenyleneiodonium chloride (DPIC) as a promising therapeutic potently active against the tested NTM. Here, we report on the detailed biological evaluation of DPIC, including in vivo efficacy in a neutropenic animal model of M. fortuitum infection.
Materials and methods

Chemicals and reagents
All bacterial media and supplements, including Middlebrook 7H9 broth, Middlebrook 7H11 agar, albumin/dextrose/catalase (ADC) and OADC, were purchased from BD (Franklin Lakes, NJ, USA). All the other chemicals and antibiotics were procured from Sigma-Aldrich. DMEM and fetal bovine serum were purchased from Lonza (USA).
Bacterial cultures and cell line
The bacterial strains utilized were M. fortuitum ATCC 6841, M. abscessus ATCC 19977, M. avium NIH-104 and M. chelonae ATCC 35752 and were procured from ATCC (ATCC, Manassas, VA, USA). The mycobacteria were propagated in Middlebrook 7H9 broth supplemented with ADC, 0.2% glycerol and 0.05% Tween 80 at appropriate temperatures. Middlebrook 7H11 agar plates supplemented with 0.2% glycerol and 10% OADC were used for bacterial cell enumeration by cfu assay. Vero cells (ATCC CCL-81) were maintained in DMEM at 37 C in an atmosphere containing 5% CO 2 .
Animal experiments
Animal experiments were performed on 6-to 8-week-old BALB/c mice procured from the National Laboratory Animal Facility of the CSIR-Central Drug Research Institute, Lucknow.
Ethics
The use of mice for infectious studies (IAEC/2014/139 dated 03.12.2014) was approved by the Institutional Animal Ethics Committee at CSIR-Central Drug Research Institute, Lucknow.
Antibacterial susceptibility testing
Antibacterial susceptibility testing was carried out utilizing broth microdilution assay according to CLSI guidelines. Stock solutions (10 mg/mL) of test and control compounds were prepared in DMSO and stored at #20 C. Bacterial cultures were inoculated in appropriate media and OD 600 of the cultures was measured, followed by dilution to achieve 10 5 cfu/mL. The compounds were tested from 64 to 0.5 mg/L in 2-fold serial diluted fashion with 2.5 lL of each concentration added per well of a 96-well roundbottom microtitre plate. Later, 97.5 lL of bacterial suspension was added to each well containing the test compound along with appropriate controls and incubation was done at appropriate temperatures for 48-72 h. The MIC was defined as the lowest compound concentration where there was no visible growth. For each compound, MICs were determined independently three times in duplicate.
Cell cytotoxicity assay
Cell toxicity was performed against Vero cells using the MTT assay. Approximately 10 3 cells/well were seeded in a 96-well plate and incubated at 37 C with an 5% CO 2 atmosphere. After 24 h, compound was added at concentrations ranging from 100 to 12.5 mg/L and incubation was done for 72 h. After the end of incubation, MTT was added at 5 mg/L concentration to each well and incubation was continued at 37 C for a further 4 h, residual medium was discarded, 0.1 mL of DMSO was added to solubilize the formazan crystals and OD was taken at 540 nm for calculating the CC 50 . CC 50 was defined as the lowest concentration of compound that led to a 50% reduction in cell viability. Doxorubicin was used as positive control and each experiment was repeated in triplicate.
Bacterial time-kill kinetics
The presence or absence of bactericidal activity was assessed using a timekill method. M. fortuitum ATCC 6841 was diluted to achieve 10 5 cfu/mL and added to a 96-well plate along with DPIC and appropriate controls at 1% and 10% MIC, followed by incubation at 37 C for 48 h. For evaluating the reduction in cfu, 0.03 mL of sample was removed at various timepoints, serially 2-fold diluted in 0.27 mL of normal saline and 0.1 mL of the respective dilution was spread on a Middlebrook 7H11 agar plate supplemented with 0.2% glycerol and 10% OADC. The plates were incubated at 37 C for 48-72 h and colonies were enumerated. Kill curves were constructed by counting the colonies from plates and plotting the cfu/mL of surviving bacteria at each timepoint in the presence and absence of compound. Each experiment was repeated three times in duplicate and the mean data are plotted.
Intracellular killing
M. fortuitum ATCC 6841 was grown overnight in 7H9 Middlebrook broth supplemented with 0.2% glycerol, 10% ADC and 0.05% Tween 80. The bacterial inoculum was prepared from mid-log phase bacteria and diluted to 10 7 cfu/mL. J774A.1 cells were seeded in six-well flat-bottom plates at 10 5 cells/well and infected with M. fortuitum at 1:5 moi. After 4 h of infection, cells were washed twice with PBS, replenished with fresh medium along with DPIC and appropriate controls and further incubated for 48 h. To estimate the initial count, three wells were lysed 4 h post-infection, serially diluted and plated on a Middlebrook 7H11 agar plate supplemented with 0.2% glycerol and 10% OADC. After 24 and 48 h of incubation, three wells were lysed, serially diluted, plated and incubated at 37 C for 72 h for estimating the cfu.
Synergy with front-line anti-mycobacterial drugs
Determination of interaction with amikacin, ceftriaxone, ceftazidime and meropenem was tested by the chequerboard method as per CLSI guidelines. Serial 2-fold dilutions of each drug were freshly prepared prior to testing. DPIC was 2-fold diluted along the ordinate ranging from 0.5 to 0.0025 mg/L (8 dilutions), while the antibiotics were serially diluted along the abscissa ranging from 64 to 0.006 mg/L for ceftriaxone, ceftazidime and meropenem, while amikacin was diluted from 8 to 0.0025 mg/L (12 dilutions) in a 96-well microtitre plate. An aliquot of 95 lL of 10 5 cfu/mL M. fortuitum was added to each well and plates were incubated at 37 C for 48 h. After the end of the incubation period, the RFICs (where FIC stands for fractional inhibitory concentration) were calculated as follows: RFIC " FIC A ! FIC B, where FIC A is the MIC of drug A in the combination/MIC of drug A alone and FIC B is the MIC of drug B in the combination/MIC of drug B alone. The combination is considered synergistic when the P FIC is 0.5, indifferent when the P FIC is . 0.5-4 and antagonistic when the P FIC is . 4.
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In vivo evaluation of DPIC in a murine neutropenic bacteraemia model of M. fortuitum
As the majority of NTM infections occur under immunocompromised conditions, we developed a murine neutropenic M. fortuitum infection model to mimic clinical conditions. Briefly, 6-week-old (18-20 g) female BALB/c mice were randomly divided into three groups: untreated (nine mice, Group 1), DPIC treated (six mice, Group 2), and amikacin treated (six mice, Group 3). Neutropenia was induced by two doses of cyclophosphamide injected intraperitoneally at 100 mg/kg, which were administered 24 h and 1 h before infection. The infection was initiated in mice by an intravenous injection of 10 7 cfu of M. fortuitum. The infected mice were treated daily with a single dose of DPIC (1 mg/kg) in Group 2 and amikacin (100 mg/kg) in Group 3 for two days, while the untreated mice in Group 1 were treated with placebo. On the third day post-infection, all the mice were sacrificed, kidney and spleen were resected and homogenized, and the bacterial burden was enumerated.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 6.0 software (GraphPad Software, La Jolla, CA, USA). Comparison between three or more groups was analysed using one-way analysis of variance, with post hoc Tukey's multiple comparisons test. P values of ,0.05 were considered to be significant.
Results and discussion
DPIC is potently effective against NTM
The most promising hit from screening the LOPAC V R library against NTM was DPIC, a potent inhibitor of NADP/NADPH oxidase, with an MIC of 0.12 mg/L for M. fortuitum (Table 1) . To determine its spectrum, it was tested against an expanded panel of NTM and demonstrated equal potency against all those tested. As can be seen in Table 1 , the MIC of DPIC was superior to most of the clinically utilized drugs for NTM, although comparable to levofloxacin.
Evaluation of cell cytotoxicity of DPIC against eukaryotic cells
The CC 50 of DPIC was determined against Vero cells to be 2.5 mg/L; thus, the selectivity index (SI " CC 50 /MIC) was calculated to be 20 (data not shown). This SI is promising enough for proceeding with the drug discovery pathway.
Bacterial killing kinetics with DPIC
To determine the killing kinetics of DPIC against NTM, it was tested at 1 % and 10 % MIC against M. fortuitum for 48 h along with meropenem and amikacin as control drugs. As can be seen in Figure 1 , treatment with DPIC at 1 % MIC caused an 4.4 log 10 reduction, while at 10 % MIC it caused an 8.2 log 10 reduction in 24 h with no regrowth at 48 h. This reduction is comparable to meropenem, which at 1 % MIC caused an 4.8 log 10 reduction and at 10 % MIC led to an 8.2 log 10 reduction in 48 h. Amikacin was more modest in its efficacy, causing a 1.9 log 10 reduction at 1 % MIC, while at 10 % MIC it was comparable to DPIC, causing an 8.2 log 10 reduction in 24 h. Taking these results together, DPIC exhibits concentration-dependent bactericidal activity against M. fortuitum that is comparable to amikacin but outcompetes meropenem. Additionally, there is no regrowth after treatment with 10 % MIC DPIC, thus potentially also reducing the chances of generating resistance.
DPIC shows efficient intracellular killing of M. fortuitum
Mycobacteria are facultative intracellular pathogens, thus the ability of DPIC to eliminate intracellular infection was determined in comparison with amikacin. Briefly, J774A.1 cells were infected with M. fortuitum and DPIC and amikacin were added to the culture at 3-10 % MIC. As can be seen in Figure 2 , at 24 h, DPIC caused a significant reduction in bacterial counts from 2.9 to 4.46 log 10 at 3-10 % MIC as compared with the untreated condition. In comparison, amikacin was much more modest, with a maximum of 1.15 log 10 reduction in 24 h at 10 % MIC when compared with the untreated condition. Taken together, these results highlight the ability of DPIC to potentially reduce the duration of therapy owing Bio-evaluation of DPIC for treatment of NTM infections JAC to its greater ability to eradicate intracellular mycobacteria as compared with amikacin.
DPIC potentiates antimicrobial efficacy of clinically utilized drugs
Due to the extremely limited antibiotic armamentarium active against NTM as well as the rapid emergence of drug resistance, combination therapy is clinically utilized for the treatment of NTM infections. In this context, the ability of DPIC to interact with amikacin, meropenem, ceftriaxone and ceftazidime was tested by calculating the FIC indexes. As can be seen in Table 2 , DPIC synergizes with all the tested drugs against M. fortuitum. This augurs well for its ability to be utilized as combination therapy for the treatment of NTM infections.
DPIC is effective in a murine neutropenic M. fortuitum bacteraemia model M. fortuitum infects immunocompetent individuals rarely; the majority of the clinical infections are seen in immunocompromised patients. In order to mimic this, we developed a murine neutropenic M. fortuitum bacteraemia model and studied the ability of DPIC to clear infection in comparison with amikacin. As can be seen in Figure 3(a and b) , DPIC at 1 mg/kg caused a reduction of 0.79 log 10 cfu in kidney and 0.44 log 10 cfu in spleen, while amikacin at 100 mg/kg caused a reduction of 1.4 log 10 in kidney and 0.4 log 10 in spleen after 48 h as compared with the untreated condition (P , 0.001). These results reveal that DPIC is as almost as effective as amikacin in reducing the bacterial load in infected mice, at one-hundredth of the dosage of amikacin. The drug discovery effort against NTM faces multiple challenges, ranging from intrinsic resistance in NTMs to paucity of animal models to verify the clinical potential of the hit compounds. 14, 15 Coupled with increasing clinical isolation of MDR NTM, the current challenge is therefore to urgently identify and develop compounds acting potentially via new targets as well as exhibiting potent activity in the presence of myriad already existing resistance mechanisms. DPIC, an NADPH/NADH oxidase inhibitor, has been shown to be active against M. tuberculosis, Mycobacterium bovis BCG and Mycobacterium smegmatis at an MIC of 0.39, 0.195 and 3.125 lM, respectively. 16 Recently, it has also been shown that DPIC inhibits growth of M. smegmatis by reducing superoxide generation. 17 To the best of our knowledge, there is no report of in vivo efficacy of DPIC available in the public domain.
In this study, we have found that DPIC is potently active against all the clinically important NTMs tested, exhibits concentrationdependent bactericidal activity, synergizes with clinically utilized drugs and eradicates intracellular infection faster and better than currently utilized therapy. Additionally, DPIC causes a comparatively equal reduction in bacterial counts in kidney and spleen when tested in a murine neutropenic bacteraemia model as compared with amikacin at one-hundredth of the dosage of amikacin. As DPIC is not an approved drug, there is paucity of detailed Figure 2 . Evaluation of efficacy of DPIC in eradicating the intracellular reservoir of mycobacterial infection as compared with amikacin, determined against M. fortuitum at different concentrations. Samples were collected at different timepoints and plated on 7H11 agar plates supplemented with OADC and incubated for 72 h at 37 C to determine the cfu count. ***P,0.001. In vivo efficacy of DPIC in a murine neutropenic M. fortuitum bacteraemia model. Mean log 10 cfu/mL in kidney (a) and spleen (b) of mice after treatment with DPIC and amikacin under neutropenic conditions. ***P,0.001.
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